Literature DB >> 11100769

Diagnosis, treatment and outcome of patients with Askin-tumors.

S Christiansen1, M Semik, B Dockhorn-Dworniczak, J Rötker, M Thomas, C Schmidt, H Jürgens, W Winkelmann, H H Scheld.   

Abstract

Askin tumors are highly malignant small-round-cell tumors of the thoracopulmonary region, which occur rarely. Therefore, we report on our experiences with eight patients (5 male, 3 females), who were treated in our department between 11'94 and 10'97 (age: 9-40 years, mean age: 20.5 years). All Askin tumors were diagnosed by histological and immunohistochemical examinations as well as molecular genetic proof of characteristic translocations. In all patients, the tumor arose from the chest wall, infiltrating adjacent ribs and parts of the lung. At the time of first diagnosis, five patients did not reveal any metastases. One patient suffered from intrapulmonary metastases and two patients from an infiltration of the diaphragm and of adjacent vertebral bodies. Treatment consisted of a pre- and postoperative (radio-) chemotherapy according to the EVAIA protocol and a radical tumor resection in all patients. The postoperative course was uneventful in seven patients, one patient suffered from pneumonia after multiple wedge resections for intrapulmonary metastases. Four patients, in whom primary tumor resection was complete, are alive 14, 20, 35 and 84 months after first diagnosis - only one patient had to undergo a second operation for a local relapse 17 months after first diagnosis. The other 4 patients, who suffered from a very extensive primary tumor, expired 13, 17, 18 and 39 months after the diagnosis was made. Our data demonstrate that Askin tumors require an aggressive multimodality treatment consisting of pre- and postoperative chemotherapy, radical surgical resection and postoperative irradiation, which may be performed preoperatively in selected cases, too.

Entities:  

Mesh:

Year:  2000        PMID: 11100769     DOI: 10.1055/s-2000-7874

Source DB:  PubMed          Journal:  Thorac Cardiovasc Surg        ISSN: 0171-6425            Impact factor:   1.827


  8 in total

1.  Askin's tumor: 11 cases and a review of the literature.

Authors:  K E Zhang; Ruijuan Lu; Pan Zhang; Shujing Shen; Xingya Li
Journal:  Oncol Lett       Date:  2015-11-10       Impact factor: 2.967

2.  Askin tumor: A rare neoplasm of thoracopulmonary region.

Authors:  Ankur Singh; Abhishek Abhinay; Abhishek Kumar; Rajniti Prasad; Amrita Ghosh; Om Prakash Mishra
Journal:  Lung India       Date:  2016 Mar-Apr

3.  Outcomes after interdisciplinary management of 7 patients with Askin tumor.

Authors:  Alireza Basharkhah; Jasmin Pansy; Christian Urban; Michael E Höllwarth
Journal:  Pediatr Surg Int       Date:  2013-02-10       Impact factor: 1.827

Review 4.  Rapidly fatal Askin's tumor: a case report and literature review.

Authors:  Mustapha Laine; Ismail Abderrahmani Ghorfi; Dalal Lambatten; Fouad Kettani; Ahmed Abid
Journal:  Pan Afr Med J       Date:  2014-05-30

5.  Interdisciplinary Radical "En-Bloc" Resection of Ewing Sarcoma of the Chest Wall and Simultaneous Chest Wall Repair Achieves Excellent Long-Term Survival in Children and Adolescents.

Authors:  Alireza Basharkhah; Herwig Lackner; Anna Karastaneva; Marko Bergovec; Stephan Spendel; Christoph Castellani; Erich Sorantin; Martin Benesch; Bernadette Liegl-Atzwanger; Freyja-Maria Smolle-Jüttner; Christian Urban; Michael Höllwarth; Georg Singer; Holger Till
Journal:  Front Pediatr       Date:  2021-03-15       Impact factor: 3.418

6.  Treatment of an Askin tumor: A case report and review of the literature.

Authors:  Xue Dou; Hongjiang Yan; Renben Wang
Journal:  Oncol Lett       Date:  2013-07-24       Impact factor: 2.967

7.  Askin's Tumor with Massive Hemoptysis.

Authors:  Mohammad Reza Lashkarizadeh; Mitra Samareh Fekri; Zahra Farahmandinia
Journal:  Tanaffos       Date:  2012

8.  Multimodal treatment of pediatric patients with Askin's tumors: our experience.

Authors:  Silvia Triarico; Giorgio Attinà; Palma Maurizi; Stefano Mastrangelo; Lorenzo Nanni; Vito Briganti; Elisa Meacci; Stefano Margaritora; Mario Balducci; Antonio Ruggiero
Journal:  World J Surg Oncol       Date:  2018-07-13       Impact factor: 2.754

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.